Dr. Wong on Investigational CAR T-Cell Products in Multiple Myeloma
Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.
Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.
One candidate is the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121), which demonstrated an overall response rate (ORR) of 73.4% and a median progression-free survival of 8.6 months in patients with relapsed/refractory disease in
JNJ-4528, another BCMA-targeted product, achieved a 100% ORR in the
These data indicate that moving CAR T-cell therapy to an earlier line of treatment may enhance response for patients, concludes Wong.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Annaiz Grimm, BS, on Using EngTregs to Treat Autoimmune Disease
August 28th 2025